Related by context. All words. (Click for frequent words.) 77 seropositive 74 seropositivity 72 seroconverted 72 BCG vaccinated 71 HIV uninfected 71 NRTI resistance 70 HBsAg 69 HCV genotype 69 CC genotype 69 antibody titer 68 coinfected 68 HLA A2 68 monoinfected 68 serologically 67 rheumatoid factor 67 immunocompetent 67 HIV seronegative 67 sero positive 67 NNRTI resistance 67 BRCA1 mutation carriers 67 HCV infected 67 viremic 67 HBeAg negative 67 CIN2 + 67 coinfection 66 lymphocytosis 66 CCR5 tropic HIV 66 genotypic resistance 66 HBeAg 66 histologically confirmed 66 anti HBs 66 HBeAg positive 66 IgM 66 euthyroid 66 pT3 66 chlamydial infection 66 IgA deficiency 66 BALB c mice 66 chronic HCV genotype 65 MRSA isolates 65 undetectable HBV DNA 65 peripheral blood mononuclear 65 genotype 1b 65 Asymptomatic 65 e antigen HBeAg 65 aged ≥ 65 genital ulcer disease 65 K ras mutations 65 serologic 65 antiretroviral naïve 65 LTBI 65 HIV coinfected 65 hepatitis C genotype 65 HCV genotypes 65 HBeAg negative patients 65 pT2 65 ASCUS 65 abnormal cytology 65 serologic testing 65 HBV infected 64 underwent resection 64 syngeneic 64 ano genital warts 64 ELISPOT 64 HCV antibody 64 HIV seropositive 64 HPV subtypes 64 hemagglutination inhibition 64 C. trachomatis 64 neoplasias 64 external genital lesions 64 PBMCs 64 HLA DRB1 * 64 anti HBc 64 immunodeficient 64 ovarian carcinoma 64 % CI #.#-#.# [003] 64 N. gonorrhoeae 64 virus HBV 64 Genotypes 64 viremia 64 K#N 64 HCV genotype 1 63 thyroglobulin 63 heterozygotes 63 enterococcal 63 homozygotes 63 HIV1 63 KRAS mutations 63 elevated ALT 63 humoral responses 63 HIV HCV coinfected 63 antibody titers 63 genotype 63 HPV-#/# 63 advanced adenoma 63 titers 63 CIN2 63 HPV# 63 latent tuberculosis infection 63 serum samples 63 HBV genotype 63 Wistar rats 63 immunized mice 63 breast carcinoma 63 Plasmodium ovale 63 HCV replicon 63 TT genotype 63 serologic tests 63 prostate carcinoma 63 hormone receptor negative 63 HGPIN 63 bronchoalveolar lavage 63 pg ml 63 P aeruginosa 63 Mantoux test 63 genotyped 63 enteroviral 63 TIMP 63 histologically proven 63 Trichomonas vaginalis 63 HBeAg positive patients 63 hypereosinophilic syndrome 63 BRAF V#E mutation 63 advanced neoplasia 63 treatment naive genotype 63 methicillin sensitive 63 discontinued Viread 63 FluCAM arm 62 BRCA2 mutation carriers 62 null responder 62 seroconversion 62 heterozygous 62 Immunohistochemical analysis 62 BALB c 62 CIN3 + 62 IgM antibodies 62 ALT flares 62 HBeAg + 62 nonpregnant 62 proband 62 underwent surgical resection 62 lamivudine resistant 62 liver transplant recipients 62 herpesviruses 62 hepatocellular carcinomas 62 HER2 expression 62 K#R [002] 62 caspofungin 62 asymptomatic carriers 62 seroprotection 62 log# copies mL 62 MenACWY 62 trichomonas 62 C#BL 6 mice 62 biochemical relapse 62 specific antigen PSA 62 tipranavir ritonavir 62 osteopenic 62 mutated K ras 62 H. influenzae 62 HBsAg positive 62 missense mutations 62 μmol L 62 advanced adenomas 62 M#V mutation 62 T1c 62 Genotype 62 n = 62 nonmetastatic 62 thyroid carcinoma 62 antibody responses 62 chronic HBV 62 Leukemias 62 achieved sustained virological 62 ELISpot 62 hyper IgE syndrome 62 CR nPR 62 virological response 62 S aureus 62 RhD negative 62 HBeAg seroconversion 62 chlamydial 62 Neisseria gonorrhoeae 62 seroprevalence 62 tuberculin skin test 62 myelodysplastic myeloproliferative diseases 62 Immunohistochemical staining 62 serological 62 Chlamydia trachomatis 62 NNRTI resistant virus 62 ertapenem 62 papillary renal cell carcinoma 62 normal karyotype 62 HPV genotypes 62 HER2 positive cancers 62 LRAT 62 CIN3 62 operable breast cancer 62 invasive carcinomas 62 prostate cancer CaP 62 breast carcinomas 62 HepC 62 grade cervical intraepithelial 62 P = .# 62 % CI #.#-#.# [007] 62 ERalpha 62 receiving VICTRELIS 62 â ‰ ¥ 62 stage IIIB 62 log# reduction 62 colorectal carcinomas 62 idiopathic PAH 61 IL#B 61 HER2 amplification 61 lupus anticoagulant 61 Cytogenetic 61 H pylori 61 treatment naïve genotype 61 oncogenic HPV 61 antiandrogens 61 cagA 61 mIU ml 61 coagulase negative staphylococci 61 clade B 61 subtyped 61 gonorrhoeae 61 S. aureus isolates 61 renal cell carcinomas 61 highest tertile 61 Sprague Dawley rats 61 basal cell nevus syndrome 61 T1DM 61 genital ulcers 61 tissue transglutaminase 61 LSIL 61 PCa 61 serogroup 61 estrogen receptor ER 61 CMV seropositive 61 methicillin resistant MRSA 61 C#Y 61 viraemia 61 germline mutations 61 HIV RNA 61 μg ml 61 castrate resistant 61 cytopathic 61 elevated LDH 61 postexposure prophylaxis 61 bronchoalveolar lavage BAL 61 onset diabetes mellitus 61 severe neutropenia 61 osteosarcomas 61 coinfected patients 61 GH deficiency 61 NMIBC 61 BRSV 61 evaluable 61 chronic HBV infection 61 relapsed MM 61 decompensated liver disease 61 pheochromocytoma 61 orchitis 61 pyelonephritis 61 liver histology 61 genotype 1a 61 neuroblastoma tumors 61 ABCB1 61 serum IGF 61 microsatellite instability 61 virologically 61 CCR5 delta# 61 pmol L 61 diabetes mellitus DM 61 abnormal pap smears 61 epididymitis 61 leiomyomas 61 genital HSV 61 EGFR mutations 61 ALT normalization 61 latent celiac disease 61 UGT#A# * 61 cytokeratin 61 recurrent glioblastoma multiforme 61 lymphadenopathy 61 COL#A# 61 stage IIIb IV 60 HER2 overexpression 60 virologic failure 60 % CI #.#-#.# [008] 60 Her2/neu 60 parasitaemia 60 REYATAZ r arm 60 elevated transaminases 60 Serologic 60 neutralizing antibody responses 60 Infectivity 60 hepatitis C HCV 60 undetectable hepatitis C 60 MLH1 60 rs# [004] 60 NHANES III 60 rs# [001] 60 genital ulcer 60 hypophosphatemia 60 gastric adenocarcinoma 60 urothelial carcinoma 60 microbiologically evaluable 60 intraperitoneally 60 ErbB2 positive 60 tuberculin skin testing 60 metastatic malignant melanoma 60 mcg BID 60 pre eclamptic 60 T2DM 60 Stage IIIb 60 anal HPV 60 HSV2 60 piperacillin tazobactam 60 invasive carcinoma 60 antiphospholipid antibodies 60 simian foamy virus 60 HER2/neu 60 Lymphocytic 60 lymphocyte counts 60 poor metabolizers 60 c KIT 60 uninfected infants 60 hyperlipidemic 60 Human Papillomavirus Quadrivalent Types 60 cytologically confirmed 60 hemorrhagic cystitis 60 HCV SPRINT 60 ribavirin therapy 60 chronic eosinophilic leukemia 60 KRAS wild 60 cervicitis 60 #beta 60 Opportunistic infections 60 vivax 60 urine cytology 60 GABHS 60 radical retropubic prostatectomy 60 Serotype 60 virologic responses 60 -#.# log# copies mL 60 HBV DNA 60 immunohistochemical staining 60 colorectal carcinoma 60 SGPT 60 fluconazole resistant 60 histologically 60 SSc 60 immunostaining 60 Prostate Lung Colorectal 60 monoinfected patients 60 Epstein Barr virus EBV 60 intraepithelial neoplasia 60 pretransplant 60 squamous intraepithelial lesions 60 amoxicillin clavulanate 60 clade C 60 noncarriers 60 SLNB 60 surgically resected 60 T SPOT.TB 60 Recombinant Vaccine 60 serum antibody 60 variant alleles 60 mg kg dose 60 serological tests 60 sCJD 60 transaminase elevations 60 cynomolgus macaques 60 bacteremic 60 CMV infection 60 IU ml 60 BRAF V#E 60 atypical hyperplasia 60 heterosexually acquired 60 intestinal metaplasia 60 umol L 60 methicillin susceptible Staphylococcus aureus 60 bacteraemia 60 evaluable subjects 60 MRSA colonization 60 BARACLUDE ® 60 lymphocyte count 60 hemodynamically significant 60 IgA antibodies 60 de novo AML 60 Subtype 60 supernatants 60 GISTs 60 TEAEs 60 TOP2A 60 epithelial tumors 60 LHRH receptor positive 60 MGUS 60 posttreatment 60 Hepatitis B Virus 60 Enterobacteriaceae 60 mg/m2 dose 60 RASSF1A 60 monozygotic twin 60 NY ESO 60 GG genotype 60 nondiabetic 60 constitutively expressed 60 ALT elevation 60 enteroviral infection 60 proctitis 60 Herpes simplex virus 60 ug dose 60 clinico pathological 60 human herpesvirus 60 adrenalectomy 60 normotensive 60 multivariate analyzes 60 pulmonary Pseudomonas aeruginosa 60 HNSCC 60 methicillin susceptible MSSA 60 pg mL 60 % CI #.#-#.# [006] 60 GSTM1 60 pulmonary metastases 60 replicon 60 Pneumocystis carinii pneumonia 60 cervical lymph nodes 60 HLA DRB1 60 Baseline characteristics 60 adenomatous polyps 60 tuberculin test 60 4CMenB 59 completely resected 59 CagA 59 ethambutol 59 chest radiographs 59 seroprotective 59 K. pneumoniae 59 sero 59 mIU mL 59 Chlamydia pneumoniae 59 metastatic neuroendocrine tumors 59 pathologic diagnosis 59 perinatally 59 pulmonary TB 59 Pharmacokinetics PK 59 progesterone receptor negative 59 immunohistochemical analysis 59 underwent radical prostatectomy 59 genotypic 59 lamivudine refractory patients 59 % Confidence Interval 59 FLT3 mutations 59 MBq 59 bladder carcinoma 59 HBV 59 Adenomas 59 recurrent UTI 59 antiretroviral naive 59 pneumoniae 59 varicella zoster virus VZV 59 reactogenicity 59 retrospective cohort 59 HBV vaccine 59 shorter telomere length 59 Flu Cy 59 ADPKD 59 FLT3 ITD 59 Trichophyton rubrum 59 adenocarcinomas 59 % CI #.#-#.# [005] 59 epithelial ovarian 59 tryptase 59 AZT zidovudine Retrovir 59 colorectal adenocarcinoma 59 serum lipid levels 59 testicular germ cell 59 affective psychosis 59 murine leukemia virus 59 seropositive patients 59 intravesical therapy 59 Klebsiella pneumonia 59 alanine aminotransferase ALT 59 undetectable virus HCV 59 micafungin 59 airway responsiveness 59 immunoreactivity 59 RhD 59 achieved ACR# 59 NAbs 59 pDCs 59 #q# deletion syndrome 59 HLA DQ2 59 confidence interval #.#-#.# 59 sexually transmitted HPV 59 eosinophilic asthma 59 pCR 59 hepatoma 59 tTG 59 Kinoid 59 TDF FTC 59 variant allele 59 -#.# log# 59 AZT 3TC 59 hamartomas 59 chronic HCV 59 unprotected receptive anal 59 vWD 59 vaccinees 59 grade cervical dysplasia 59 TMC# r 59 total thyroidectomy 59 HLA DR2 59 expressors 59 etiologic agent 59 eosinophil count 59 Leydig cell 59 IgG antibodies 59 basal cell carcinoma BCC 59 HCV infections 59 hypogonadal 59 serum HBV DNA 59 demyelinating 59 Clusterin 59 grade squamous intraepithelial 59 histological subtype 59 beta estradiol 59 axillary node 59 posaconazole 59 autologous SCT 59 deletion 5q 59 plasmacytoid 59 ceftazidime 59 BRCA2 carriers 59 Gram stain 59 herpes zoster shingles 59 mediastinitis 59 M#V 59 IgG antibody 59 surface antigen HBsAg 59 antiandrogen 59 S. suis 59 HTLV 59 GARDASIL ® 59 nonnucleoside reverse transcriptase inhibitors 59 oral squamous cell 59 confidence interval CI 59 Candida infection 59 Virologic 59 efavirenz EFV 59 promoter methylation 59 Rh factor 59 3TC lamivudine Epivir 59 receptive anal sex 59 superinfection 59 atrophic gastritis 59 adverse cytogenetics 59 allele frequencies 59 susceptible isolates 59 VNTR 59 neoplasm 59 polyposis 59 BRCA2 mutations 59 fructose intolerance 59 cervical lesions 59 cTnT 59 aminotransferase 59 detectable HCV RNA 59 univariate analysis 59 quinolone resistant 59 oropharyngeal candidiasis OPC 59 squamous histology 59 Bordetella pertussis 59 CD8 responses 59 metastatic prostate 59 recurrent metastatic 59 LRTI 59 colorectal adenoma 59 serovar 59 del 5q 59 overt hypothyroidism 59 Herpes Simplex Virus 59 experimentally infected 59 KRAS mutations occur 59 polyomavirus 59 indinavir 59 CP CPPS 59 hydronephrosis 59 Protease Inhibitors 59 CsA 59 elevated triglyceride levels 59 unprotected anal 59 HLA DR 59 pyrimethamine 59 initiating antiretroviral therapy 59 hematological parameters 59 TP# mutations 59 oseltamivir resistant 59 saline placebo 59 abacavir lamivudine 59 lymphovascular invasion 59 axillary lymph nodes 58 allelic variants 58 Neutrophil 58 flutamide 58 fluoroquinolone resistance 58 receiving antiretroviral therapy 58 PTPN# 58 duplex ultrasonography 58 endometrial carcinoma 58 hydroxyvitamin D levels 58 combination antiretroviral therapy 58 precancers 58 anogenital warts 58 folate concentrations 58 thrombocytopenic 58 alpha2 58 HLA B 58 peritoneal fluid 58 atopic 58 HCV RESPOND 2 58 PegIFN RBV 58 Human papillomavirus 58 HRCT 58 valacyclovir 58 gene polymorphism 58 neoplastic 58 immunosuppressed 58 resistant isolates 58 Ad5 58 capsular polysaccharide 58 endometritis 58 antibody titres 58 p# biomarker 58 lymphopenia 58 HLA B# 58 mL/min/#.# m 2 58 neutropenia dehydration dyspnea 58 pancreatic adenocarcinoma 58 adiponectin concentrations 58 mcg albinterferon alfa 2b 58 mg TID 58 relapsed ALL 58 nondiabetic patients 58 thymidine kinase 58 nodal metastases 58 JAK2 V#F 58 cytogenetic abnormalities 58 karyotypes 58 gonococcal 58 serous ovarian cancer 58 idiopathic membranous nephropathy 58 chorioamnionitis 58 associated lymphoid tissue 58 anemia hemoglobin 58 haematological 58 gastric carcinoma 58 urethritis 58 Gag polymorphisms 58 6 mercaptopurine 58 liver transplantations 58 Typhimurium 58 HCV antibodies 58 serostatus 58 allele frequency 58 Immune responses 58 mRNA expression 58 Parathyroid Hormone 58 MTHFR 58 ALI ARDS 58 HLA DR4 58 T#I [002] 58 heavily pretreated 58 IFN α 58 methicillin susceptible 58 neutralizing antibody 58 lowest tertile 58 Infected Patients 58 histologies 58 abnormal Pap smear 58 histologic subtype 58 PPSV# 58 EBV infection 58 nodal metastasis 58 BRCA2 gene mutation 58 rifamycins 58 quadrivalent human papillomavirus 58 hypercholesterolemic patients 58 posttransplant 58 neutrophil counts 58 prevalences 58 Ribavirin causes 58 Serum concentrations 58 Endometrial 58 nmol liter 58 highly immunogenic 58 chloride secretion 58 Papillary 58 Bacteremia 58 downregulated 58 potent antiretroviral therapy 58 MIC# [001] 58 isoprostane 58 severe rotavirus gastroenteritis 58 autoimmune thyroid 58 BRAF V# mutation 58 HIV coinfection 58 L. pneumophila 58 chronic HCV infection 58 cervical intraepithelial neoplasia 58 Protease inhibitor 58 tuberculous 58 TNFalpha 58 hepatorenal syndrome 58 Hepatitis B virus 58 P. falciparum malaria 58 inducible nitric oxide synthase 58 μg L 58 CANCIDAS 58 acute myeloid 58 haematologic 58 transgenic rats 58 Univariate analysis 58 Babesia 58 aggressive systemic mastocytosis 58 nulliparous women 58 demonstrated antitumor activity 58 immunoglobulin G 58 receiving immunosuppressive therapy 58 mcg dose 58 GSTP1 58 bone scintigraphy 58 ß blockers 58 β blockers 58 Acute Myeloid Leukaemia AML 58 IgM antibody 58 obstructive coronary artery 58 Trichinella 58 LV ejection fraction 58 bone marrow stromal cells 58 imatinib therapy 58 biochemical recurrence 58 ERBB2 58 noninfected 58 CYP#C# * 58 cervical vaginal 58 chlorambucil 58 Pegylated Interferon 58 C#BL/#J 58 comparator arm 58 IgG4 58 Gleevec resistant 58 mucosal inflammation 58 cervical carcinoma 58 pregnancy bacterial vaginosis 58 gene polymorphisms 58 IPAH 58 mutated KRAS 58 inhibin B 58 varicella chickenpox 58 Streptococcus agalactiae 58 ritonavir boosted 58 microdeletions 58 anti JCV antibodies 58 microg 58 oncogenic HPV types 58 ovarian endometrial 58 Measles mumps 58 gestational hypertension 58 rFSH 58 cells uL 58 INTRON therapy 58 genital human papillomavirus 58 lopinavir r arm 58 SNP rs# [001] 58 KRAS mutation 58 autoantibody positive 58 hsCRP levels 58 clinicopathological features 58 penicillin resistant 58 HBeAg negative chronic hepatitis 58 kDa protein 58 Herpes Simplex 58 TURBT 58 candidemia 58 chlamydial infections 58 alanine aminotransferase 58 virus HCV 58 chlamydia gonorrhea syphilis 58 virus XMRV 58 NSCLC tumors 58 plasma pharmacokinetics 58 antiviral prophylaxis 58 intra articular injection 58 polysaccharide vaccines 58 CLL SLL 58 nutlin 3a 58 genotypes 58 Salmonella typhi 58 serum IgE 58 MetS 58 isoenzyme 58 AST ALT 58 scintigraphic 58 pegIFN 58 skeletal metastases 58 HepG2 cells 58 locoregional recurrence 58 dapagliflozin plus 58 abnormal Pap smears 58 median CD4 58 alpha1 58 nevirapine Viramune 58 ribavirin RBV 58 gemcitabine carboplatin 58 invasive ductal 58 hyperplastic 58 experienced virologic failure 58 immune globulin intravenous 58 postintervention 58 BRCA mutation carriers 58 Inhibin B 58 pyrazinamide 58 Supplementary Table 58 Prostate specific antigen 58 microalbumin test 58 patients coinfected 57 generalized edema 57 non pledgers 57 thrombophilia 57 prostate adenocarcinoma 57 pelvic lymphadenectomy 57 Viral Load 57 Human Papillomavirus HPV 57 nonobese 57 ALT elevations 57 rotaviruses 57 S. enterica 57 prepubertal 57 undergone radical prostatectomy 57 parous women 57 dual tropic 57 CCR5 tropic 57 enfuvirtide 57 murine models 57 methicillin resistant S. aureus 57 airway hyperresponsiveness 57 cranial irradiation 57 idiopathic myelofibrosis 57 TRAIL R1 57 cytomegalovirus infection 57 undergone splenectomy 57 trimethoprim sulfamethoxazole 57 polycythemia vera essential thrombocythemia 57 mIU L 57 immunological responses 57 stool specimens 57 C. pneumoniae 57 pertussis toxin 57 dermatophytes 57 achieve sustained virological 57 serodiscordant couples 57 malignant nodules 57 baseline LDH 57 leukopenia 57 nonischemic 57 LPS induced 57 hepatitis B infection 57 PEG IFN 57 cytomegalovirus CMV 57 Serological 57 precursor lesions 57 granulocytes 57 lymphocytic 57 Cervista HPV HR 57 Bezielle 57 anthracycline containing 57 rhGH 57 HLA antigens 57 IFN gamma 57 LC#m# vaccine 57 Enterobacter cloacae 57 liposomal amphotericin B 57 hypercholesterolemic 57 metastatic malignant 57 M. bovis 57 genital herpes infections 57 HSCT 57 vaginal lesions 57 maternal serum 57 patients evaluable 57 cSSSIs 57 recurrent acute pancreatitis 57 gestational diabetes mellitus 57 cefotaxime 57 parainfluenza virus 57 hypermethylated 57 LEXIVA r 57 FOLFIRI alone 57 mucosal lesions 57 inhibin 57 Allogeneic 57 intestinal biopsy 57 del 5q MDS 57 hemagglutination inhibition HAI 57 HCV Genotype 57 selective modulator 57 immunohistochemistry IHC 57 imipenem 57 pegylated alpha interferon 57 preeclamptic 57 MAGE A3 protein 57 TIMP 1 57 NRTI backbone 57 Acute myeloid leukemia 57 serotype #A 57 MYCN amplification 57 serum urate levels 57 trastuzumab Herceptin ® 57 virulence genes 57 extramedullary 57 SSc patients 57 Subgroup analyzes 57 leukocyte count 57 ng dL 57 pyrexia mucositis sepsis febrile 57 mosaicism 57 fluvastatin 57 splenectomized patients 57 odds ratios ORs 57 serum creatinine levels 57 Varicella zoster virus 57 Peg IFN 57 FLT3 57 carcinoids 57 viral titers 57 hepatitis B immunoglobulin 57 prior chemotherapy regimens 57 undergone hysterectomy 57 mitoxantrone chemotherapy 57 papillary carcinoma 57 #mg BID [001] 57 Adjuvant chemotherapy 57 interferon IFN 57 DAS# CRP 57 IGFBP 57 congenital deficiency 57 cytologic 57 salpingo oophorectomy 57 asymptomatic 57 SHBG levels 57 familial aggregation 57 tumor necrosis 57 mucinous 57 renal pelvis 57 visceral metastases 57 GBA mutations 57 CD4 lymphocyte count 57 Naive Patients 57 receptor tyrosine kinase inhibitor 57 serum concentrations 57 lopinavir r 57 A. phagocytophilum 57 situ CIS 57 #.#ng/ml 57 recurrent genital herpes 57 circulating endothelial cells 57 Haemophilus influenzae 57 pneumocystis 57 peritoneal cancer 57 serum estradiol 57 invasive lobular 57 sonographically 57 receptor blocker 57 alveolar epithelial cells 57 enterocolitis 57 C trachomatis 57 microbiological eradication 57 colorectal neoplasms 57 RhD positive 57 anagrelide 57 BRCA mutations 57 metastatic lymph nodes 57 TACI mutations 57 influenzae 57 protease inhibitors PIs 57 Recombinant interferon alpha 57 MDA MB 57 Kaplan Meier analysis 57 D#N 57 plasma folate 57 TNF α 57 nasopharyngeal specimens 57 HbF 57 tigecycline 57 precancerous cervical lesions